Remission Induction initially consists of prednisone (28 days), vincristine (4 weekly doses), daunorubicin (1 to 3 weekly doses), and pegaspargase (2 doses). The second part (given over 2 weeks and overlapping with the last week of the first part of induction) consists of cyclophosphamide, cytarabine, and mercaptopurine combinations. Patients with B-ALL will be randomized for administration of a dose of rituximab on Day 3 prior to the first dose of pegaspargase to prevent sensitization to asparaginase and subsequent asparaginase reaction and to improve anti-leukemia outcome. Dasatinib will be added for patients with Ph+ and Ph-like ABL1-class fusions and bortezomib will be given to patients with no targetable lesions and Day 15 minimal residual disease (MRD) >5%.